Esperion Offers Results Of Five Studies Of Heart Drug

Plymouth-based Esperion Therapeutics Monday announced the results from a Phase 1 study and four preclinical studies for its heart disease drug candidate ETC-1002. Initial results look promising.

WWJ Newsradio 950–05/02/2011


Esperion Starts Phase 2 Trial Of Cholesterol Buster

The Plymouth pharmaceutical developer Esperion Therapeutics Thursday announced that it has initiated a Phase 2 clinical study for ETC-1002, the company’s lead product candidate.  ETC-1002 is a novel small molecule compound that has demonstrated preclinical […]